İsrail - İbranice - Ministry of Health

j-c health care ltd - infliximab - אבקה להכנת תרכיז לאינפוזיה - infliximab 100.0 mg/vial - infliximab - infliximab - - adult :crohn's disease: treatment of severe active crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. treatment of fistulising crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. -paediatric crohn's disease: remicade is indicated for: treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy -ankylosing spondylitis: remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional ther

İsrail - İbranice - Ministry of Health

padagis israel agencies ltd, israel - infliximab - תמיסה להזרקה - infliximab 120 mg/ml - infliximab

İsrail - İbranice - Ministry of Health

j-c health care ltd - guselkumab - תמיסה להזרקה - guselkumab 100 mg / 1 ml - guselkumab

İsrail - İbranice - Ministry of Health

trima israel pharmaceutical products maabarot ltd - clobetasol propionate - קרם - clobetasol propionate 0.05 %w/w - clobetasol

İsrail - İbranice - Ministry of Health

novartis israel ltd - etanercept - תמיסה להזרקה - etanercept 25 mg / 0.5 ml - etanercept

İsrail - İbranice - Ministry of Health

novartis israel ltd - etanercept - תמיסה להזרקה - etanercept 50 mg / 1 ml - etanercept

İsrail - İbranice - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - תמיסה להזרקה - abatacept 125 mg/ml - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists.

İsrail - İbranice - Ministry of Health

abbvie biopharmaceuticals ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 100 mg / 1 ml - adalimumab

İsrail - İbranice - Ministry of Health

dexcel ltd, israel - betamethasone as dipropionate; calcipotriol as monohydrate - קצף לעור - betamethasone as dipropionate 0.5 mg / 1 g; calcipotriol as monohydrate 50 mcg / 1 g - calcipotriol, combinations

İsrail - İbranice - Ministry of Health

dexcel ltd, israel - betamethasone as dipropionate; calcipotriol as monohydrate - קצף לעור - betamethasone as dipropionate 0.5 mg / 1 g; calcipotriol as monohydrate 50 mcg / 1 g - calcipotriol, combinations